Developer docs
API playgroundTry for free, no card

Search company profiles

HemoGenyx

Full company profile

uuid0000ohv

Namestring
HemoGenyx
Legal namestring
Hemogenyx Pharmaceuticals plc
Websiteurl
hemogenyx.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

HemoGenyx Pharmaceuticals plc is a clinical-stage biopharmaceutical company developing cell and antibody therapies for blood cancers, autoimmune diseases, and viral infections. Its lead clinical asset is HG-CT-1 (HEMO-CAR-T), an autologous CAR-T cell therapy constructed using a proprietary humanised monoclonal antibody against the FLT3 receptor overexpressed on acute myeloid leukaemia (AML) cells; HG-CT-1 is currently in Phase I clinical trials for adult and pediatric (12-18) relapsed/refractory AML, with early data showing CAR-T expansion, blast reductions, and a manageable safety profile. The pipeline also includes CDX, a FLT3-targeting bispecific antibody licensed exclusively from Eli Lilly for AML treatment and bone-marrow transplant conditioning; CBR, a Chimeric Bait Receptor platform that programs myeloid immune cells against viruses (proof-of-concept for SARS-CoV-2) and certain cancers; Hu-PHEC cell therapy licensed from Cornell; and proprietary Advanced Hematopoietic Chimera (AHC) humanised mouse models used as a research and drug-discovery engine.

The company has no commercial products or licensing revenue; it operates as a pre-revenue R&D entity, funding operations entirely through periodic equity placings on UK public markets. The business model targets upfront payments, milestone payments, and royalties from out-licensing its therapies to larger pharmaceutical partners for commercialisation. Manufacturing has transitioned from in-house clean-room production at its Manhattanville, New York laboratory to CDMO Made Scientific (technology transfer completed March 2026), with a parallel early-commercialisation pathway being established in Estonia via Cellin Technologies OÜ under the hospital exemption route. The company is headquartered in London (UK company number 08401609), with R&D operations in New York through wholly-owned subsidiaries Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, and trades on the London Stock Exchange Main Market (LSE: HEMO) following its December 2025 admission.

Short descriptiontext

HemoGenyx Pharmaceuticals is a London-headquartered, LSE-listed clinical-stage biopharma developing CAR-T cell therapy (HG-CT-1), bispecific antibodies, and immune-cell programming platforms to treat relapsed/refractory acute myeloid leukaemia, other blood diseases, and viral infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, bispecific antibodies, acute myeloid leukemia, clinical-stage biopharmaceuticals, immunotherapy development
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage biopharmaceutical drug development
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biopharmaceutical company. Business model aims to license therapies to partners for upfront payments, research funding, milestone payments, and royalty streams. Products have not yet reached commercialization.

stocktitan.net
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel cell therapies and immunotherapies for blood cancers (notably acute myeloid leukemia), viral infections, and autoimmune diseases. Its lead product candidate HEMO-CAR-T (HG-CT-1) is a CAR-T cell therapy in Phase I clinical trials for relapsed/refractory AML, while the pipeline also includes the CDX bi-specific antibody for AML treatment and transplant conditioning and the CBR (Chimeric Bait Receptor) immunotherapy platform. The company intends to commercialize its therapies through licensing to pharmaceutical partners, generating upfront, milestone, and royalty revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • DSMB authorized progression to dose-expansion phase and pediatric arm opening for HG-CT-1 Phase I trial
+2 more records
Product overview1 text field

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of distinct and complementary products for blood and autoimmune diseases. The core product portfolio includes HEMO-CAR-T (HG-CT-1), a CAR-T cell therapy for Acute Myeloid Leukemia currently in Phase I clinical trials; CDX Bi-Specific Antibody for AML treatment and bone marrow transplant conditioning; and the CBR (Chimeric Bait Receptor) platform technology for targeting cancer and infectious diseases. The company also holds a license to the Hu-PHEC cell therapy approach and has developed Advanced Hematopoietic Chimeras (AHC) as proprietary research models. These products are at varying stages of development, with HEMO-CAR-T being the most advanced clinical program.

Product and service3 records
1HEMO-CAR-T (HG-CT-1)
CategoryCell therapy / CAR-T immunotherapy
Description

A CAR-T cell therapy that reprograms a patient's own T cells to recognize and destroy acute myeloid leukemia (AML) cells, using the company's proprietary humanized monoclonal antibody against the FLT3 protein overexpressed on AML blasts. Intended for adult and pediatric patients (aged 12-18) with relapsed/refractory AML who have failed or are refractory to standard treatments.

2CDX Bi-Specific Antibody
CategoryBi-specific antibody therapy
Description

A bi-specific antibody that redirects patients' own immune cells to eliminate FLT3+ AML cells and hematopoietic stem cells, intended for treatment of relapsed/refractory AML and for less toxic conditioning of patients undergoing bone marrow or hematopoietic stem cell transplantation. Developed in collaboration with Eli Lilly under an exclusive worldwide license.

3CBR (Chimeric Bait Receptor) Immunotherapy Platform
CategoryEngineered cell therapy / immunotherapy platform
Description

A novel immunotherapy platform that programs or redirects myeloid immune cells (such as macrophages) using synthetic proteins to combat viral infections and certain types of cancer, with proof of concept demonstrated for SARS-CoV-2. The platform is modular and can be reconfigured to target a wide range of viruses, bacteria, and malignant cells.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-18
Description

Contract research organization (CRO) providing clinical services for upcoming Phase I clinical trial for CAR-T therapy targeting AML under contract with Prevail Partners investment arrangement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Development collaboration concluded in 2021 resulting in selection of CDX antibody clone ready for IND-enabling studies. In October 2021, Hemogenyx secured exclusive worldwide license for all applications to intellectual property developed by Lilly related to CDX bispecific antibody.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Master Translational Research Services Agreement entered January 2021 with Penn, world's leading experts in CAR-T therapies, to advance HEMO-CAR-T toward and through clinical trials. Intended outcome is clinical proof of concept for HEMO-CAR-T.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration announced May 2018 to develop new lupus therapies using company's Advanced Hematopoietic Chimera (AHC) platform.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematological malignancies including B-cell lymphoma; comparable as a peer clinical-stage CAR-T developer targeting blood cancers with a similar asset profile to HEMO-CAR-T.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic ("off-the-shelf") CAR-T therapies for hematological cancers; directly comparable to Hemogenyx as a peer CAR-T developer pursuing similar indications with similar modality.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic CAR-T therapies for hematological malignancies, including AML; directly comparable as a peer in CAR-T for blood cancers.

TypeDirect peer
Description

Clinical-stage biotech developing gene-edited allogeneic CAR-T cell therapies for hematological malignancies; directly comparable to Hemogenyx as a CAR-T platform peer.

TypeDirect peer
Description

Clinical-stage biotech developing iPSC-derived NK and T-cell therapies for cancer and autoimmune diseases; directly comparable as a peer cell therapy developer with overlapping indications.

TypeDirect peer
Description

Clinical-stage biotech focused on hematopoietic stem cell engineering and AML therapies, including transplant conditioning; directly comparable as a peer addressing AML and bone marrow transplant conditioning.

TypeDirect peer
Description

Clinical-stage biotech developing novel conditioning agents and stem cell transplant therapies; directly comparable as a peer in hematopoietic stem cell transplant conditioning, overlapping with Hemogenyx's CDX program.

TypeDirect peer
Description

Clinical-stage biotech developing programmed T-cell therapies for hematological cancers; directly comparable as a peer CAR-T developer with similar modality and target indications.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with multiple approved CAR-T therapies (Breyanzi, Abecma) and a broad hematology/oncology franchise; comparable as the dominant incumbent in CAR-T and blood cancer therapeutics against which Hemogenyx is competing.

TypeBroad incumbent
Description

Major CAR-T franchise (Yescarta, Tecartus) within Gilead Sciences targeting hematological malignancies; comparable as a broad incumbent defining the CAR-T competitive landscape Hemogenyx is entering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HemoGenyx

Clinical-stage biopharmaceutical drug developmenthemogenyx.com

HemoGenyx Pharmaceuticals is a London-headquartered, LSE-listed clinical-stage biopharma developing CAR-T cell therapy (HG-CT-1), bispecific antibodies, and immune-cell programming platforms to treat relapsed/refractory acute myeloid leukaemia, other blood diseases, and viral infections.

What HemoGenyx does

HemoGenyx Pharmaceuticals plc is a clinical-stage biopharmaceutical company developing cell and antibody therapies for blood cancers, autoimmune diseases, and viral infections. Its lead clinical asset is HG-CT-1 (HEMO-CAR-T), an autologous CAR-T cell therapy constructed using a proprietary humanised monoclonal antibody against the FLT3 receptor overexpressed on acute myeloid leukaemia (AML) cells; HG-CT-1 is currently in Phase I clinical trials for adult and pediatric (12-18) relapsed/refractory AML, with early data showing CAR-T expansion, blast reductions, and a manageable safety profile. The pipeline also includes CDX, a FLT3-targeting bispecific antibody licensed exclusively from Eli Lilly for AML treatment and bone-marrow transplant conditioning; CBR, a Chimeric Bait Receptor platform that programs myeloid immune cells against viruses (proof-of-concept for SARS-CoV-2) and certain cancers; Hu-PHEC cell therapy licensed from Cornell; and proprietary Advanced Hematopoietic Chimera (AHC) humanised mouse models used as a research and drug-discovery engine.

The company has no commercial products or licensing revenue; it operates as a pre-revenue R&D entity, funding operations entirely through periodic equity placings on UK public markets. The business model targets upfront payments, milestone payments, and royalties from out-licensing its therapies to larger pharmaceutical partners for commercialisation. Manufacturing has transitioned from in-house clean-room production at its Manhattanville, New York laboratory to CDMO Made Scientific (technology transfer completed March 2026), with a parallel early-commercialisation pathway being established in Estonia via Cellin Technologies OÜ under the hospital exemption route. The company is headquartered in London (UK company number 08401609), with R&D operations in New York through wholly-owned subsidiaries Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, and trades on the London Stock Exchange Main Market (LSE: HEMO) following its December 2025 admission.

HemoGenyx firmographics

Firmographics
Name
HemoGenyx
Legal name
Hemogenyx Pharmaceuticals plc
Website
https://hemogenyx.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
HemoGenyx Pharmaceuticals is a London-headquartered, LSE-listed clinical-stage biopharma developing CAR-T cell therapy (HG-CT-1), bispecific antibodies, and immune-cell programming platforms to treat relapsed/refractory acute myeloid leukaemia, other blood diseases, and viral infections.
Ownership category
akta.pro rank

HemoGenyx industry classification

Industry
Product category
Clinical-stage biopharmaceutical drug development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • CAR-T cell therapy
  • Bispecific antibodies
  • Acute myeloid leukemia
  • Clinical-stage biopharmaceuticals
  • Immunotherapy development

Where HemoGenyx is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

HemoGenyx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Licensing and Royalty Revenue: Pre-revenue clinical-stage biopharmaceutical company. Business model aims to license therapies to partners for upfront payments, research funding, milestone payments, and royalty streams. Products have not yet reached commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

HemoGenyx product offering

Product offering

Core offering

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel cell therapies and immunotherapies for blood cancers (notably acute myeloid leukemia), viral infections, and autoimmune diseases. Its lead product candidate HEMO-CAR-T (HG-CT-1) is a CAR-T cell therapy in Phase I clinical trials for relapsed/refractory AML, while the pipeline also includes the CDX bi-specific antibody for AML treatment and transplant conditioning and the CBR (Chimeric Bait Receptor) immunotherapy platform. The company intends to commercialize its therapies through licensing to pharmaceutical partners, generating upfront, milestone, and royalty revenue.

Product overview

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of distinct and complementary products for blood and autoimmune diseases. The core product portfolio includes HEMO-CAR-T (HG-CT-1), a CAR-T cell therapy for Acute Myeloid Leukemia currently in Phase I clinical trials; CDX Bi-Specific Antibody for AML treatment and bone marrow transplant conditioning; and the CBR (Chimeric Bait Receptor) platform technology for targeting cancer and infectious diseases. The company also holds a license to the Hu-PHEC cell therapy approach and has developed Advanced Hematopoietic Chimeras (AHC) as proprietary research models. These products are at varying stages of development, with HEMO-CAR-T being the most advanced clinical program.

Differentiator

Problem solved

Functional benefit

Products and services

  • HEMO-CAR-T (HG-CT-1) A CAR-T cell therapy that reprograms a patient's own T cells to recognize and destroy acute myeloid leukemia (AML) cells, using the company's proprietary humanized monoclonal antibody against the FLT3 protein overexpressed on AML blasts. Intended for adult and pediatric patients (aged 12-18) with relapsed/refractory AML who have failed or are refractory to standard treatments.
  • CDX Bi-Specific Antibody A bi-specific antibody that redirects patients' own immune cells to eliminate FLT3+ AML cells and hematopoietic stem cells, intended for treatment of relapsed/refractory AML and for less toxic conditioning of patients undergoing bone marrow or hematopoietic stem cell transplantation. Developed in collaboration with Eli Lilly under an exclusive worldwide license.
  • CBR (Chimeric Bait Receptor) Immunotherapy Platform A novel immunotherapy platform that programs or redirects myeloid immune cells (such as macrophages) using synthetic proteins to combat viral infections and certain types of cancer, with proof of concept demonstrated for SARS-CoV-2. The platform is modular and can be reconfigured to target a wide range of viruses, bacteria, and malignant cells.

Quantifiable outcome

  • DSMB authorized progression to dose-expansion phase and pediatric arm opening for HG-CT-1 Phase I trial
  • +2 more outcomes

Companies that use HemoGenyx

Customer profile

Segments3 records

Ideal customer profiles2 records

HemoGenyx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

HemoGenyx partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Prevail InfoWorksminorStrategic or Co-development Partner · 18 September 2023Contract research organization (CRO) providing clinical services for upcoming Phase I clinical trial for CAR-T therapy targeting AML under contract with Prevail Partners investment arrangement.
  • Eli Lilly & Co.coreStrategic or Co-development PartnerDevelopment collaboration concluded in 2021 resulting in selection of CDX antibody clone ready for IND-enabling studies. In October 2021, Hemogenyx secured exclusive worldwide license for all applications to intellectual property developed by Lilly related to CDX bispecific antibody.
  • University of PennsylvaniacoreStrategic or Co-development PartnerMaster Translational Research Services Agreement entered January 2021 with Penn, world's leading experts in CAR-T therapies, to advance HEMO-CAR-T toward and through clinical trials. Intended outcome is clinical proof of concept for HEMO-CAR-T.
  • Rockefeller UniversityminorStrategic or Co-development PartnerResearch collaboration announced May 2018 to develop new lupus therapies using company's Advanced Hematopoietic Chimera (AHC) platform.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

HemoGenyx competitors and assessment

Company assessment

Direct peers

  • Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematological malignancies including B-cell lymphoma; comparable as a peer clinical-stage CAR-T developer targeting blood cancers with a similar asset profile to HEMO-CAR-T.
  • Allogene Therapeutics: Clinical-stage biotech developing allogeneic ("off-the-shelf") CAR-T therapies for hematological cancers; directly comparable to Hemogenyx as a peer CAR-T developer pursuing similar indications with similar modality.
  • Precision Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T therapies for hematological malignancies, including AML; directly comparable as a peer in CAR-T for blood cancers.
  • Cellectis: Clinical-stage biotech developing gene-edited allogeneic CAR-T cell therapies for hematological malignancies; directly comparable to Hemogenyx as a CAR-T platform peer.
  • Fate Therapeutics: Clinical-stage biotech developing iPSC-derived NK and T-cell therapies for cancer and autoimmune diseases; directly comparable as a peer cell therapy developer with overlapping indications.
  • Vor BioPharma: Clinical-stage biotech focused on hematopoietic stem cell engineering and AML therapies, including transplant conditioning; directly comparable as a peer addressing AML and bone marrow transplant conditioning.
  • Jasper Therapeutics: Clinical-stage biotech developing novel conditioning agents and stem cell transplant therapies; directly comparable as a peer in hematopoietic stem cell transplant conditioning, overlapping with Hemogenyx's CDX program.
  • Autolus Therapeutics: Clinical-stage biotech developing programmed T-cell therapies for hematological cancers; directly comparable as a peer CAR-T developer with similar modality and target indications.

Broad incumbents

  • Bristol Myers Squibb: Large pharmaceutical company with multiple approved CAR-T therapies (Breyanzi, Abecma) and a broad hematology/oncology franchise; comparable as the dominant incumbent in CAR-T and blood cancer therapeutics against which Hemogenyx is competing.
  • Gilead (Kite Pharma): Major CAR-T franchise (Yescarta, Tecartus) within Gilead Sciences targeting hematological malignancies; comparable as a broad incumbent defining the CAR-T competitive landscape Hemogenyx is entering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

HemoGenyx social profiles

Digital presence

HemoGenyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HemoGenyx leadership team

Management profile

Number of profiles

Profiles6 records

HemoGenyx subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

HemoGenyx funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HemoGenyx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HemoGenyx

What does HemoGenyx do?

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel cell therapies and immunotherapies for blood cancers (notably acute myeloid leukemia), viral infections, and autoimmune diseases. Its lead product candidate HEMO-CAR-T (HG-CT-1) is a CAR-T cell therapy in Phase I clinical trials for relapsed/refractory AML, while the pipeline also includes the CDX bi-specific antibody for AML treatment and transplant conditioning and the CBR (Chimeric Bait Receptor) immunotherapy platform. The company intends to commercialize its therapies through licensing to pharmaceutical partners, generating upfront, milestone, and royalty revenue.

Is HemoGenyx a public or private company?

HemoGenyx is a public company. It is classified as public and is currently operating.

When was HemoGenyx founded?

HemoGenyx was founded in 2013. It employs 1 to 10 people.

Where is HemoGenyx based?

HemoGenyx is headquartered in New York, United States, in the North America region.

How does HemoGenyx make money?

One revenue line is on record: licensing and Royalty Revenue.

Who are HemoGenyx's main competitors?

Direct peers on record are Caribou Biosciences, Allogene Therapeutics, Precision Biosciences, Cellectis, Fate Therapeutics, Vor BioPharma, Jasper Therapeutics and Autolus Therapeutics. Broad incumbents are Bristol Myers Squibb and Gilead (Kite Pharma).

Does HemoGenyx have an API?

No public API is recorded for HemoGenyx.

What industry is HemoGenyx in?

HemoGenyx's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegateChairman Receives Prestigious AwardHemogenyx Pharmaceuticals Chairman Sir Marc Feldmann received the Robert Koch Medal in Gold from the Robert Koch Foundation for lifetime achievement in immunology. The award recognized his work on TNF blockade, which became the first biological therapy for autoimmune disease and is now standard care. He continues to focus on translational research and supporting young scientists.FinancialContent Business PageHemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious AwardHemogenyx Pharmaceuticals Chairman Professor Sir Marc Feldmann received the Robert Koch Medal in Gold from the Robert Koch Foundation for lifetime achievement in immunology. The award recognized his work on TNF blockade, which became the first biological therapy for autoimmune disease and is now standard care. He was knighted in 2010 and continues to guide the company's clinical programs.InvestegateFirst Patient Treated in Second Adult Dose CohortHemogenyx Pharmaceuticals announced the first patient treated in the second adult dose cohort of its HG-CT-1 CAR-T trial for relapsed or refractory acute myeloid leukemia. The patient received twice the dose of the first cohort, following DSMB safety review with no dose-limiting toxicities. Recruitment to the pediatric arm is underway.AdvfnHemogenyx Pharmaceuticals PLC First Patient Treated in Second Adult Dose CohortHemogenyx Pharmaceuticals announced the first patient treated in the second adult dose cohort of its HG-CT-1 CAR-T Phase I trial for relapsed or refractory acute myeloid leukemia. The patient received twice the dose of the first cohort, following DSMB safety review with no dose-limiting toxicities. Recruitment to the pediatric arm is underway.Stock TitanHemogenyx Pharmaceuticals starts second Phase I cohortHemogenyx Pharmaceuticals announced the first patient treated in the second adult dose cohort of its Phase I trial of HG-CT-1 CAR-T therapy for relapsed or refractory AML. The patient received twice the first cohort's dose, with five prior patients unable to be treated due to disease progression. The company continues recruiting for the cohort and the pediatric arm.YahooHemogenyx Pharmaceuticals PLC Announces Feasibility Study AgreementHemogenyx Pharmaceuticals announced a feasibility study with Nitto Denko to evaluate targeted lipid nanoparticle delivery of its FLT3-targeting CAR mRNA to human T cells. The study, expected to take about four months, is the first step toward an in vivo CAR-T approach that could convert the therapy into an off-the-shelf product. The company's ongoing Phase I trial of HG-CT-1 remains its principal focus.FinancialContent Business PageHemogenyx Pharmaceuticals PLC Announces Feasibility Study AgreementHemogenyx Pharmaceuticals entered a feasibility study agreement with Nitto Denko to test delivery of its FLT3-CAR mRNA to human T cells using Nitto's ctLNP technology. The study, expected to take four months, is the first step toward an in vivo CAR-T approach that could convert the therapy into an off-the-shelf product. The company's ongoing Phase I trial of HG-CT-1 remains its principal focus.Stock TitanHemogenyx Enters Nitto Feasibility Study AgreementHemogenyx Pharmaceuticals entered a feasibility study agreement with Nitto Denko to evaluate whether Nitto's cell-targeted lipid nanoparticle technology can deliver Hemogenyx's FLT3-targeting CAR mRNA to human T cells. The in vitro study, expected to take about four months, is the company's first step toward an in vivo CAR-T approach, which could enable a drug-like, off-the-shelf product. The ongoing Phase I trial of HG-CT-1 remains unaffected.Ticker ReportHemogenyx Pharmaceuticals (LON:HEMO) Posts Quarterly Earnings ResultsHemogenyx Pharmaceuticals reported quarterly EPS of GBX 101.70 on Monday. The stock opened at GBX 472, up 1.7%, with a market cap of £32.10 million. The company focuses on blood disease therapies, including CAR-T and stem cell products.YahooHemogenyx Pharmaceuticals PLC Announces Half-year Financial ReportHemogenyx Pharmaceuticals reported its half-year results for the six months ended 30 June 2026, raising £5.6 million and recording a pre-tax loss of £6.56 million. The company completed manufacturing transfer to Made Scientific and secured a binding agreement with Cellin for early commercialisation in Estonia. It plans to escalate the HG-CT-1 trial in adults and begin paediatric recruitment.